William O Hahn, K Rachael Parks, Mingchao Shen, Gabriel Ozorowski, Holly Janes, Lamar Ballweber-Fleming, Amanda S Woodward Davis, Chris Duplessis, Mark Tomai, Antu K Dey, Zachary K Sagawa, Stephen C De Rosa, Aaron Seese, Latha Kallur Siddaramaiah, Leonidas Stamatatos, Wen-Hsin Lee, Leigh M Sewall, Dalton Karlinsey, Hannah L Turner, Vanessa Rubin, Sarah Furth, Kellie MacPhee, Michael Duff, Lawrence Corey, Michael C Keefer, Srilatha Edupuganti, Ian Frank, Janine Maenza, Lindsey R Baden, Ollivier Hyrien, Rogier W Sanders, John P Moore, Andrew B Ward, Georgia D Tomaras, David C Montefiori, Nadine Rouphael, M Juliana McElrath
UNLABELLED: Stabilized trimers preserving the native-like HIV envelope structure may be key components of a preventive HIV vaccine regimen to induce broadly neutralizing antibodies (bnAbs). We evaluated trimeric BG505 SOSIP.664 gp140, formulated with a novel TLR7/8 signaling adjuvant, 3M-052-AF/Alum, for safety, adjuvant dose-finding and immunogenicity in a first-in-healthy adult (n=17), randomized, placebo-controlled trial (HVTN 137A). The vaccine regimen appeared safe. Robust, trimer-specific antibody, B-cell and CD4+ T-cell responses emerged post-vaccination...
May 9, 2024: medRxiv